Cronos Group And Ginkgo Bioworks Announce Achievement Milestone In Cultured Cannabinoids Partnership; Cronos Says Has 'successfully achieved the productivity target for cannabigerolic acid'

Author: Bill Haddad | August 23, 2021 07:35am

Cronos Group, Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos Group"), an innovative global cannabinoid company, and Ginkgo Bioworks ("Ginkgo"), which is building the leading horizontal platform for cell programming, today announced the achievement of the first target productivity milestone in their partnership to produce eight cultured cannabinoids. Ginkgo, which recently announced a business combination with Soaring Eagle Acquisition Corp. (NASDAQ:SRNG), serves customers across industries seeking to develop new and better products using biology. Using Ginkgo's platform for organism design and development, Cronos Group has successfully achieved the productivity target for cannabigerolic acid (CBGA), which will support the Cronos Group's planned CBG product launch this fall.

Posted In: CRON SRNG TSX:CRON